|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Tsuchiya SI, Yamaguchi R, Tsuchiya K and
Ohashi R: Characteristics of the Japanese histological
classification for breast cancer: Correlations with imaging and
cytology. Breast Cancer. 23:534–539. 2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ahmed S, Sami A and Xiang J: HER2-Directed
therapy: Current treatment options for HER2-positive breast cancer.
Breast Cancer. 22:101–116. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Wuerstlein R and Harbeck N: Neoadjuvant
therapy for HER2-positive breast cancer. Rev Recent Clin Trials.
12:81–92. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kubo M, Kawai M, Kumamaru H, Miyata H,
Tamura K, Yoshida M, Ogo E, Nagahashi M, Asaga S, Kojima Y, et al:
A population-based recurrence risk management study of patients
with pT1 node-negative HER2+ breast cancer: A national
clinical database study. Breast Cancer Res Treat. 178:647–656.
2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Goldvaser H, Korzets Y, Shepshelovich D,
Yerushalmi R, Sarfaty M, Ribnikar D, Thavendiranathan P and Amir E:
Deescalating adjuvant trastuzumab in HER2-positive early-stage
breast cancer: A systemic review and meta-analysis. JNCI Cancer
Spectr. 3(pkz033)2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Hirsova P, Ibrahim SH, Krishnan A, Verma
VK, Bronk SF, Werneburg NW, Charlton MR, Shah VH, Malhi H and Gores
GJ: Lipid-Induced signaling causes release of inflammatory
extracellular vesicles from hepatocytes. Gastroenterology.
150:956–967. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Gu G, Dustin D and Fuqua SA: Targeted
therapy for breast cancer and molecular mechanisms of resistance to
treatment. Curr Opin Pharmacol. 31:97–103. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Gomez-Casati DF and Busi MV: Clinical
Molecular Medicine. In: Principles and Practice. 1st Edition. Kumar
D (ed.) Academic Press, pp47-55, 2019.
|
|
10
|
Wang D, Li W, Zou Q, Yin L, Du Y, Gu J and
Suo J: Serum metabolomic profiling of human gastric cancer and its
relationship with the prognosis. Oncotarget. 8:110000–110015.
2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Chinnaiyan P, Kensicki E, Bloom G, Prabhu
A, Sarcar B, Kahali S, Eschrich S, Qu X, Forsyth P and Gillies R:
The metabolomic signature of malignant glioma reflects accelerated
anabolic metabolism. Cancer Res. 72:5878–5888. 2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hadi NI, Jamal Q, Iqbal A, Shaikh F,
Somroo S and Musharraf SG: Serum metabolomic profiles for breast
cancer diagnosis, grading and staging by gas chromatography-mass
spectrometry. Sci Rep. 7(1715)2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kumar N, Shahjaman M, Mollah MN, Islam SM
and Hoque MA: Serum and plasma metabolomic biomarkers for lung
cancer. Bioinformation. 13:202–208. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Miolo G, Muraro E, Caruso D, Crivellari D,
Ash A, Scalone S, Lombardi D, Rizzolio F, Giordano A and Corona G:
Pharmacometabolomics study identifies circulating spermidine and
tryptophan as potential biomarkers associated with the complete
pathological response to trastuzumab-paclitaxel neoadjuvant therapy
in HER-2 positive breast cancer. Oncotarget. 7:39809–39822.
2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chiba M, Kubota S, Sakai A and Monzen S:
Cell-To-Cell communication via extracellular vesicles among human
pancreatic cancer cells derived from the same patient. Mol Med Rep.
18:3989–3996. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Yan JJ, Jung JS, Lee JE, Lee J, Huh SO,
Kim HS, Jung KC, Cho JY, Nam JS, Suh HW, et al: Therapeutic effects
of lysophosphatidylcholine in experimental sepsis. Nat Med.
10:161–167. 2004.PubMed/NCBI View
Article : Google Scholar
|
|
17
|
van Meer G, Voelker DR and Feigenson GW:
Membrane lipids: Where they are and how they behave. Nat Rev Mol
Cell Biol. 9:112–124. 2008.PubMed/NCBI View
Article : Google Scholar
|
|
18
|
Shamseddine AA, Airola MV and Hannun YA:
Roles and regulation of neutral sphingomyelinase-2 in cellular and
pathological processes. Adv Biol Regul. 57:24–41. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Andrews NW, Corrotte M and Castro-Gomes T:
Above the fray: Surface remodeling by secreted lysosomal enzymes
leads to endocytosis-mediated plasma membrane repair. Semin Cell
Dev Biol. 45:10–17. 2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Nami B and Wang Z: HER2 in breast cancer
stemness: A negative feedback loop towards trastuzumab resistance.
Cancers (Basel). 26(40)2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Wilks ST: Potential of overcoming
resistance to HER2-targeted therapies through the PI3K/Akt/mTOR
pathway. Breast. 24:548–555. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kim JS, Kim HA, Seong MK, Seol H, Oh JS,
Kim EK, Chang JW, Hwang SG and Noh WC: STAT3-Survivin signaling
mediates a poor response to radiotherapy in HER2-positive breast
cancers. Oncotarget. 7:7055–7065. 2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Candas D and Li JJ: MKP1 mediates
resistance to therapy in HER2-positive breast tumors. Mol Cell
Oncol. 2(e997518)2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Adada M, Luberto C and Canals D:
Inhibitors of the sphingomyelin cycle: Sphingomyelin synthases and
sphingomyelinases. Chem Phys Lipids. 197:45–59. 2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Signorelli P and Hannun YA: Analysis and
quantitation of ceramide. Methods Enzymol. 345:275–294.
2002.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Elsherbini A and Bieberich E: Ceramide and
exosomes: A novel target in cancer biology and therapy. Adv Cancer
Res. 140:121–154. 2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Chiba M, Kubota S, Sato K and Monzen S:
Exosomes released from pancreatic cancer cells enhance angiogenic
activities via dynamin-dependent endocytosis in endothelial cells
in vitro. Sci Rep. 8(11972)2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Chiba M, Monzen S, Iwaya C, Kashiwagi Y,
Yamada S, Hosokawa Y, Mariya Y, Nakamura T and Wojcik A: Serum
miR-375-3p increase in mice exposed to a high dose of ionizing
radiation. Sci Rep. 8(1302)2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kosaka N, Iguchi H, Hagiwara K, Yoshioka
Y, Takeshita F and Ochiya T: Neutral sphingomyelinase 2
(nSMase2)-dependent exosomal transfer of angiogenic microRNAs
regulate cancer cell metastasis. J Biol Chem. 288:10849–10859.
2013.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Revill K, Wang T, Lachenmayer A, Kojima K,
Harrington A, Li J, Hoshida Y, Llovet JM and Powers S: Genome-Wide
methylation analysis and epigenetic unmasking identify tumor
suppressor genes in hepatocellular carcinoma. Gastroenterology.
145:1424–1435. 2013.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zheng K, Chen Z, Feng H, Chen Y, Zhang C,
Yu J, Luo Y, Zhao L, Jiang X and Shi F: Sphingomyelin synthase 2
promotes an aggressive breast cancer phenotype by disrupting the
homoeostasis of ceramide and sphingomyelin. Cell Death Dis.
10(157)2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Lebok P, von Hassel A, Meiners J,
Hube-Magg C, Simon R, Höflmayer D, Hinsch A, Dum D, Fraune C, Göbel
C, et al: Up-regulation of lysophosphatidylcholine acyltransferase
1 (LPCAT1) is linked to poor prognosis in breast cancer. Aging
(Albany NY). 11:7796–7804. 2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Abdelzaher E and Mostafa MF:
Lysophosphatidylcholine acyltransferase 1 (LPCAT1) upregulation in
breast carcinoma contributes to tumor progression and predicts
early tumor recurrence. Tumor Biol. 36:5473–5483. 2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Kim IC, Lee JH, Bang G, Choi SH, Kim YH,
Kim KP, Kim HK and Ro J: Lipid profiles for HER2-positive breast
cancer. Anticancer Res. 33:2467–2472. 2013.PubMed/NCBI
|
|
35
|
de Oliveira Taveira M, Nabavi S, Wang Y,
Tonellato P, Esteva FJ, Cantley LC and Wulf GM: Genomic
characteristics of trastuzumab-resistant her2-positive metastatic
breast cancer. J Cancer Res Clin Oncol. 143:1255–1262.
2017.PubMed/NCBI View Article : Google Scholar
|
